DYN logo

Dyne Therapeutics Inc. (DYN)

$25.14

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on DYN

Market cap

$4.69B

EPS

-3.26

P/E ratio

--

Price to sales

--

Dividend yield

--

Beta

1.077987

Price on DYN

Previous close

$25.10

Today's open

$25.55

Day's range

$24.92 - $26.18

52 week range

$11.92 - $27.31

Profile about DYN

CEO

John G. Cox

Employees

258

Headquarters

Waltham, MA

Exchange

Nasdaq Global Select

Shares outstanding

186746431

Issue type

Common Stock

DYN industries and sectors

Healthcare

Biotechnology & Life Sciences

News on DYN

Dyne Therapeutics to Present Preclinical Data for Multiple Development Candidates for Duchenne Muscular Dystrophy (DMD) at 27th Annual NMSG Scientific Meeting

- Data support the ongoing development of four investigational therapies for DMD amenable to skipping of exons 53, 45, 44 or 55, all of which are advancing into IND-enabling studies - - All development candidates leverage the same FORCE™ platform as zeleciment rostudirsen (z-rostudirsen, also known as DYNE-251), which is under FDA review for exon 51 DMD - WALTHAM, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that it will present preclinical data supporting the ongoing development of DYNE-253, DYNE-245, DYNE-244 and DYNE-255 for the potential treatment of DMD amenable to skipping of exons 53, 45, 44 and 55, respectively, at the 27th Annual Neuromuscular Study Group (NMSG) Scientific Meeting being held September 25-27, 2026, in San Antonio, TX.

news source

GlobeNewsWire • 21 hours ago

news preview

Dyne Therapeutics to Participate in Upcoming Investor Conferences

WALTHAM, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc . (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that management is scheduled to participate in the following upcoming investor conferences:

news source

GlobeNewsWire • Sep 2, 2026

news preview

Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WALTHAM, Mass., Aug. 20, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that it has granted inducement equity awards to 11 newly hired employees. The awards were made as an inducement material to the newly hired employees' acceptance of employment with Dyne in accordance with Nasdaq Listing Rule 5635(c)(4).

news source

GlobeNewsWire • Aug 20, 2026

news preview

Dyne Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights

- Biologics License Application (BLA) for z-rostudirsen in exon 51 DMD accepted for review by FDA; Priority Review granted; PDUFA target action date set for January 21, 2027 -

news source

GlobeNewsWire • Jul 29, 2026

news preview

Dyne Therapeutics Announces U.S. FDA Clearance of Investigational New Drug (IND) Application for DYNE-302 in Facioscapulohumeral Muscular Dystrophy (FSHD)

- Company's third program to enter clinical development leveraging FORCE platform with the goal of delivering functional improvement in rare neuromuscular disease -

news source

GlobeNewsWire • Jul 28, 2026

news preview

Dyne Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares

WALTHAM, Mass., July 23, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced the closing of its previously announced upsized underwritten public offering of 21,045,000 shares of its common stock at a public offering price of $20.50 per share, which includes 2,745,000 shares issued upon the exercise in full by the underwriters of their option to purchase additional shares of common stock in the offering.

news source

GlobeNewsWire • Jul 23, 2026

news preview

Dyne Therapeutics Announces Proposed Public Offering of Common Stock

WALTHAM, Mass., July 21, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that it has commenced an underwritten public offering of $300,000,000 of shares of its common stock. Dyne also intends to grant the underwriters a 30-day option to purchase up to an additional $45,000,000 of shares of its common stock. All of the shares in the proposed offering are to be sold by Dyne.

news source

GlobeNewsWire • Jul 21, 2026

news preview

Dyne Therapeutics Announces Pricing of Upsized $375 Million Public Offering of Common Stock

WALTHAM, Mass., July 21, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced the pricing of an upsized underwritten public offering of 18,300,000 shares of its common stock at a public offering price of $20.50 per share. The gross proceeds to Dyne from the offering, before deducting underwriting discounts and commissions and offering expenses payable by Dyne, are expected to be $375,150,000. All shares in the offering are being sold by Dyne. The offering is expected to close on or about July 23, 2026, subject to customary closing conditions. In addition, Dyne has granted the underwriters a 30-day option to purchase up to an additional 2,745,000 shares of its common stock at the public offering price, less the underwriting discounts and commissions.

news source

GlobeNewsWire • Jul 22, 2026

news preview

DYN Stock Rises 19.2% in 3 Months: What's Driving the Rally?

Dyne gains momentum as FDA priority review for its lead DMD therapy and progress in its DM1 program strengthen confidence in its pipeline.

news source

Zacks Investment Research • Jul 21, 2026

news preview

Dyne Therapeutics Trades Sideways Over An FDA Hurdle. Is It Time To Take Profits?

Dyne Therapeutics stock briefly jumped Monday after the FDA agreed to review the company's muscular dystrophy drug.

news source

Investors Business Daily • Jul 20, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Dyne Therapeutics Inc.

Open an M1 investment account to buy and sell Dyne Therapeutics Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in DYN on M1